Trial Profile

Efficacy and Safety of Oral Octreolin in Patients With Acromegaly Who Are Currently Receiving Parenteral Somatostatin Analogs

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 07 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Octreotide (Primary)
Indications Acromegaly
Focus Registrational; Therapeutic Use
Sponsors Chiasma

Most Recent Events

31 Aug 2015 According to a Chiasma media release, the agency has set a target review date under the Prescription Drug User Fee Act (PDUFA) of April 15, 2016.
17 Aug 2015 According to a Chiasma media release, the U.S. FDA has accepted for filing the company's NDA for octreotide capsules for the maintenance therapy of adult patients with acromegaly.
16 Jun 2015 According to a Chiasma media release, the company has submitted a New Drug Application for the Octreotide capsules to the US FDA as the maintenance treatment of adults with acromegaly, based on the results of this trial in June 2015.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com